BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAF V600E metastatic melanoma
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAF
V600E
metastatic melanoma
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 108, Issue 4, Pages 924-931
Publisher
Springer Nature
Online
2013-02-13
DOI
10.1038/bjc.2013.29
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma
- (2012) Georgina V. Long et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Prognostic Value of BRAF V600 Mutations in Melanoma Patients After Resection of Metastatic Lymph Nodes
- (2012) Stéphanie Moreau et al. ANNALS OF SURGICAL ONCOLOGY
- 18F-labelled fluorodeoxyglucose–positron emission tomography (FDG–PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma
- (2012) Matteo S. Carlino et al. EUROPEAN JOURNAL OF CANCER
- Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
- (2012) Gerald S Falchook et al. LANCET
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- (2012) Georgina V Long et al. LANCET ONCOLOGY
- Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine
- (2012) J. S. Wilmott et al. MOLECULAR CANCER THERAPEUTICS
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma
- (2012) Molly Yancovitz et al. PLoS One
- Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance
- (2012) Hubing Shi et al. Nature Communications
- Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases
- (2011) David Capper et al. ACTA NEUROPATHOLOGICA
- Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody
- (2011) David Capper et al. ACTA NEUROPATHOLOGICA
- NRAS mutation status is an independent prognostic factor in metastatic melanoma
- (2011) John A. Jakob et al. CANCER
- Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma
- (2011) Georgina V. Long et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Taking stock of translational research in melanoma at the 2010 Society for Melanoma Research Congress
- (2010) Keith T. Flaherty Pigment Cell & Melanoma Research
- Polyclonality of BRAF Mutations in Acquired Melanocytic Nevi
- (2009) Jingrong Lin et al. JNCI-Journal of the National Cancer Institute
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now